Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: gonnahappensoon who wrote (8308)	11/21/2009 8:21:31 AM
From: me otter	Read Replies (1) \| Respond to of 63324

I think we are safe. As secrets are hard to keep at IMMU, I think you would have seen a huge spike with gigantic volume. It was a nice close though and I would expect some of the short interest is beginning to wonder whether they will get the chance to cover under the $3 level.

To: gonnahappensoon who wrote (8308)	11/21/2009 11:13:38 AM
From: idahoranch1	Read Replies (1) \| Respond to of 63324

Yes, there was strong buying in the last couple of hours, also note the last couple of minutes. The shorts dumped over 100,000 shares in the last couple of minutes to try to push the stock down and take away as much of the gain as they could, it sure didn't go down as much as it would have in the past because there are institutions buying. The company has been on several road shows over the last week or two, ranging from the East coast to California to Canada, and more to do this coming week. These are "stipulated by the company" "non-deal" road shows. I understand that a lot of money managers they talk to are aware of E-mab and SLE, but many had not picked up on the pancreatic cancer trial with hPAM4. If nothing else, a lot of money managers are being put on alert as to that product. Since the institutional ownership increased by almost 30% last quarter, one could speculate that some of it was because of E-mab, and the jump at the time UCB came out with top line data verifies that to some degree. But it will be a while before we get more data on that and the shorts have done their best to diffuse any confidence that data by heavy shorting and maybe even getting an analyst and a writer or two to slam the company and that trial data (which was only top line, they had almost no details to attack). Still, it looks to me like institutions continue to accumulate. I don't think hPAM4 has been much of a factor in the institutions buying. I think that is about to change. We will see data around January on about 24 patients. Data was released on 11 patients in June, but only two of those 11 were at 12mc (the third one was not yet evaluable, responses seem to be established at the 8 and 12 week follow up). So I see these road shows as not only bringing money managers up to speed on E-mab and V-mab and DNL and other pipeline products, but they are setting the table for ASCO-GI. The data on the first 11 patients is intriguing, but not yet convincing. Only two of those 11 patients had gotten to the 8 week follow up at 12mc, the rest were at the lowest dose, 4 patients at 6.5mc/m2 and 4 at 9mc/m2 with one of those dropping out before being half way through the treatment because of an infection in his abdomen. The data released in January will add about a dozen more patients. I think 3 of those will be at the 15mc/m2 dose and the rest at 12mc/m2. CONT